Campbell & CO Investment Adviser LLC Viking Therapeutics, Inc. Transaction History

Campbell & CO Investment Adviser LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$17.4 - $94.5 $438,184 - $2.38 Million	-25,183 Reduced 86.01%	4,095 $335,000
Q4 2023 Feb 13, 2024	BUY	$9.24 - $19.64 $270,528 - $575,019	29,278 New	29,278 $544,000
Q2 2023 Aug 11, 2023	BUY	$14.84 - $24.79 $274,183 - $458,020	18,476 New	18,476 $299,000
Q1 2022 May 09, 2022	SELL	$3.0 - $4.88 $160,800 - $261,568	-53,600 Closed	0 $0
Q4 2021 Feb 10, 2022	BUY	$4.6 - $6.72 $246,559 - $360,192	53,600 New	53,600 $247,000

473

66.2M

5.72M

3.39M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $4.03B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Campbell & CO Investment Adviser LLC, based on Form 13F filings with the SEC.

Stay updated on Campbell & CO Investment Adviser LLC with notifications on news.